DaVita Inc. (NYSE:DVA) Receives $161.80 Consensus Price Target from Brokerages

DaVita Inc. (NYSE:DVA) has been given a consensus rating of “Hold” by the five ratings firms that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, three have given a hold recommendation and one has assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $161.80.

A number of equities research analysts have issued reports on DVA shares. Barclays increased their price target on DaVita from $150.00 to $164.00 and gave the stock an “equal weight” rating in a research note on Thursday. Bank of America increased their price target on DaVita from $139.00 to $145.00 and gave the stock an “underperform” rating in a research note on Wednesday, August 7th. Truist Financial increased their price target on DaVita from $165.00 to $175.00 and gave the stock a “hold” rating in a research note on Monday, October 7th. TD Cowen raised their price objective on DaVita from $139.00 to $150.00 and gave the company a “hold” rating in a research report on Wednesday, July 24th. Finally, UBS Group raised their price objective on DaVita from $169.00 to $175.00 and gave the company a “buy” rating in a research report on Thursday, August 8th.

Insiders Place Their Bets

In other DaVita news, insider Kathleen Alyce Waters sold 7,857 shares of the firm’s stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $146.21, for a total value of $1,148,771.97. Following the completion of the sale, the insider now owns 83,011 shares of the company’s stock, valued at $12,137,038.31. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other news, insider Kathleen Alyce Waters sold 7,857 shares of DaVita stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $146.21, for a total transaction of $1,148,771.97. Following the completion of the sale, the insider now owns 83,011 shares of the company’s stock, valued at approximately $12,137,038.31. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, COO Michael David Staffieri sold 9,539 shares of DaVita stock in a transaction that occurred on Thursday, August 15th. The shares were sold at an average price of $150.03, for a total transaction of $1,431,136.17. Following the sale, the chief operating officer now directly owns 241,945 shares of the company’s stock, valued at $36,299,008.35. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 173,482 shares of company stock valued at $27,387,069 over the last 90 days. Insiders own 2.00% of the company’s stock.

Institutional Trading of DaVita

Several hedge funds and other institutional investors have recently bought and sold shares of DVA. Harvard Management Co. Inc. purchased a new position in shares of DaVita in the 2nd quarter worth approximately $55,115,000. Lazard Asset Management LLC grew its position in shares of DaVita by 147.3% in the 1st quarter. Lazard Asset Management LLC now owns 256,872 shares of the company’s stock worth $35,460,000 after buying an additional 153,008 shares during the last quarter. Andra AP fonden grew its position in shares of DaVita by 9.0% in the 2nd quarter. Andra AP fonden now owns 192,300 shares of the company’s stock worth $26,647,000 after buying an additional 15,800 shares during the last quarter. abrdn plc grew its position in shares of DaVita by 1.2% in the 3rd quarter. abrdn plc now owns 189,065 shares of the company’s stock worth $30,719,000 after buying an additional 2,180 shares during the last quarter. Finally, Jupiter Asset Management Ltd. grew its position in shares of DaVita by 146.7% in the 1st quarter. Jupiter Asset Management Ltd. now owns 187,177 shares of the company’s stock worth $25,840,000 after buying an additional 111,311 shares during the last quarter. Institutional investors own 90.12% of the company’s stock.

DaVita Price Performance

NYSE DVA opened at $141.59 on Friday. The business’s fifty day moving average price is $157.71 and its 200-day moving average price is $146.17. The stock has a market capitalization of $11.61 billion, a price-to-earnings ratio of 15.27, a PEG ratio of 0.79 and a beta of 0.89. The company has a debt-to-equity ratio of 15.78, a current ratio of 1.37 and a quick ratio of 1.12. DaVita has a 1-year low of $76.64 and a 1-year high of $168.50.

DaVita (NYSE:DVA) last released its quarterly earnings results on Tuesday, October 29th. The company reported $2.59 earnings per share for the quarter, missing the consensus estimate of $2.76 by ($0.17). The firm had revenue of $3.26 billion for the quarter, compared to the consensus estimate of $3.25 billion. DaVita had a net margin of 6.53% and a return on equity of 88.18%. DaVita’s quarterly revenue was up 4.6% compared to the same quarter last year. During the same period in the previous year, the company earned $2.85 earnings per share. On average, equities analysts predict that DaVita will post 9.73 earnings per share for the current year.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.